# EDGAR Filing Document

**Accession Number:** 0000876343
**File Stem:** 0000950170-25-109396
**Filing Date:** 2025-8
**Character Count:** 19594
**Document Hash:** 2ca9651b33f2d6fd955ed2f120770380
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-109396.hdr.sgml**: 20250815

**ACCESSION NUMBER**: 0000950170-25-109396

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20250815

**DATE AS OF CHANGE**: 20250815

**EFFECTIVENESS DATE**: 20250815

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lineage Cell Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000876343
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943127919
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289644
- **FILM NUMBER:** 251224830

**BUSINESS ADDRESS:**
- **STREET 1:** 2173 SALK AVENUE
- **STREET 2:** SUITE 200
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92008
- **BUSINESS PHONE:** 5105213390

**MAIL ADDRESS:**
- **STREET 1:** 2173 SALK AVENUE
- **STREET 2:** SUITE 200
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92008

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIOTIME INC
- **DATE OF NAME CHANGE:** 19930328

**As filed with the Securities and Exchange Commission on August 15, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

***REGISTRATION STATEMENT UNDER***

***THE SECURITIES ACT OF 1933***

**Lineage Cell Therapeutics, Inc.**

(Exact name of Registrant as specified in its charter)

---

| | |
|:---|:---|
| **California**<br>(State or other jurisdiction of<br>incorporation or organization) | **94-3127919**<br>(I.R.S. employer<br>identification number) |
| **2173 Salk Avenue, Suite 200, Carlsbad, CA**<br>(Address of principal executive offices) | **92008**<br>(Zip Code) |

---

**Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan**

(Full title of the plan)

**George A. Samuel III**

**General Counsel and Secretary**

**Lineage Cell Therapeutics, Inc.**

**2173 Salk Avenue, Suite 200 Carlsbad, CA 92008**

(Name and address of agent for service)

**(442) 287-8990**

(Telephone number, including area code, of agent for service)

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

Lineage Cell Therapeutics, Inc. ("Lineage"), is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the "Commission") to register an additional 19,500,000 common shares of Lineage for issuance under the Lineage 2021 Equity Incentive Plan (the "2021 Plan"). At Lineage's annual meeting of shareholders held on June 26, 2025, Lineage's shareholders approved an amendment to the 2021 Plan to increase the number of common shares reserved for issuance thereunder by 19,500,000.

Lineage filed with the Commission: (a) a Registration Statement on Form S-8 on September 28, 2021 (File No. 333-259853) (the "2021 Registration Statement") to register an aggregate of 30,358,599 common shares available for issuance under the 2021 Plan, consisting of (i) 15,000,000 shares and (ii) an estimated 15,358,599 Prior Plan Returning Shares (as defined in the 2021 Plan); and (b) a Registration Statement on Form S-8 on November 13, 2023 (File No. 333-275505) (the "2023 Registration Statement" and together with the 2021 Registration Statement, the "Prior Registration Statements") to register an additional 19,500,000 common shares for issuance under the 2021 Plan.

This Registration Statement registers an additional 19,500,000 common shares for issuance under the 2021 Plan, thereby increasing the total number of common shares available for issuance under the 2021 Plan to an amount not to exceed the sum of (i) 54,000,000 shares and (ii) the Prior Plan Returning Shares, if any, as such shares become available from time to time.

This Registration Statement relates to securities of the same class as those registered under the Prior Registration Statements and is being filed in accordance with General Instruction E to Form S-8. Pursuant to such instruction, the contents of the Prior Registration Statements related to the 2021 Plan are hereby incorporated by reference in and made part of this Registration Statement, except to the extent supplemented, superseded or modified by the specific information set forth below and/or the specific exhibits attached under Item 8 hereto, pursuant to Rule 412 under the Securities Act of 1933, as amended (the "Securities Act").

In accordance with the instructional Note to Part I of Form S-8, the information specified by Part I of Form S-8 has been omitted from this Registration Statement for offers of common shares pursuant to the 2021 Plan. The documents containing the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428(b)(1) under the Securities Act.

------

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

---

| | |
|:---|:---|
| **Item 8.** | **Exhibits** |

---

The following exhibits are filed as a part of or incorporated by reference into this Registration Statement:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| <br>**Exhibit No.** | <br>**Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** | <br>**Filed Herewith** |
| 5.1 | [<u>Opinion of Sheppard, Mullin, Richter & Hampton, LLP</u>](lctx-ex5_1.htm) |  |  |  |  | X |
| 23.1 | [<u>Consent of Baker Tilly US, LLP</u>](lctx-ex23_1.htm) |  |  |  |  | X |
| 23.2 | [<u>Consent of WithumSmith+Brown, PC</u>](lctx-ex23_2.htm) |  |  |  |  | X |
| 23.3 | [<u>Consent of Sheppard, Mullin, Richter & Hampton, LLP (included in Exhibit 5.1)</u>](lctx-ex5_1.htm) |  |  |  |  | X |
| 24.1 | [<u>Power of Attorney (contained on the signature page of this Registration Statement)</u>](#poa) |  |  |  |  | X |
| 99.1(a)  | [<u>Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan</u>](https://www.sec.gov/Archives/edgar/data/876343/000149315221022765/ex10-1.htm) | 8-K | 001-12830-211254211 | 10.1 | 09/15/2021 |  |
| 99.1(b) | [<u>Amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan</u>](https://www.sec.gov/Archives/edgar/data/876343/000149315223025680/formdef14a.htm) | 8-K | 001-12830-231242967 | 10.1 | 09/06/2023 |  |
| 99.1(c) | [<u>Amendment No. 2 to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan</u>](https://www.sec.gov/Archives/edgar/data/876343/000095017025060090/lctx-20250429.htm) | 8-K | 001-12830-251101532 | 10.1 | 07/02/2025 |  |
| 99.1(d) | [<u>Form of Stock Option Grant Notice and Agreement for Employees and Consultants under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan</u>](https://www.sec.gov/Archives/edgar/data/876343/000149315221023990/ex99-2.htm) | 10-Q | 001-12830-211396840 | 10.4 | 11/10/2021 |  |
| 99.1(e) | [<u>Form of Stock Option Grant Notice and Agreement for Non-Employee Directors under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan</u>](https://www.sec.gov/Archives/edgar/data/876343/000149315221023990/ex99-3.htm) | 10-Q | 001-12830-211396840 | 10.5 | 11/10/2021 |  |
| 99.1(f) | [<u>Form of Restricted Stock Unit Award Grant Notice and Agreement under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan</u>](https://www.sec.gov/Archives/edgar/data/876343/000149315221023990/ex99-4.htm) | 10-Q | 001-12830-211396840 | 10.6 | 11/10/2021 |  |
| 107.1 | [<u>Filing Fee Table</u>](lctx_exfilingfees.htm) |  |  |  |  | X |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California, on August 15, 2025.

---

| | |
|:---|:---|
| LINEAGE CELL THERAPEUTICS, INC. | LINEAGE CELL THERAPEUTICS, INC. |
| By: | */s/ Brian M Culley* |
| Name: | Brian M Culley |
| Title: | Chief Executive Officer |

---

KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned officers and directors of Lineage Cell Therapeutics, Inc., constitutes and appoints Brian M. Culley and Jill Ann Howe, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and on his or her behalf and in his or her name, place and stead, in any and all capacities, to sign, execute and file this Registration Statement under the Securities Act of 1933, as amended, and any one or more amendments to any part of this Registration Statement, including any post- effective amendments, or appendices or supplements that may be required to be filed under the Securities Act of 1933, as amended, to keep such Registration Statement effective or to terminate its effectiveness, with all exhibits and any and all documents required to be filed with respect thereto, with the Securities and Exchange Commission or any regulatory authority, granting unto such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises in order to effectuate the same, as fully to all intents and purposes as he or she himself or herself might or could do, if personally present, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Brian M. Culley* | Chief Executive Officer and Director | August 15, 2025 |
| Brian M. Culley | *(Principal Executive Officer)* |  |
| */s/ Jill Ann Howe* | Chief Financial Officer | August 15, 2025 |
| Jill Ann Howe | *(Principal Financial and Accounting Officer)* |  |
| */s/ Michael H. Mulroy* | Chair of the Board | August 15, 2025 |
| Michael H. Mulroy |  |  |
| */s/ Dipti Amin*  | Director | August 15, 2025 |
| Dipti Amin |  |  |
| */s/ Deborah Andrews* | Director | August 15, 2025 |
| Deborah Andrews |  |  |
| */s/ Neal C. Bradsher* | Director | August 15, 2025 |
| Neal C. Bradsher |  |  |
| */s/ Anula Jayasuriya* | Director | August 15, 2025 |
| Anula Jayasuriya |  |  |
| */s/ Angus C. Russell* | Director | August 15, 2025 |
| Angus C. Russell |  |  |

---

------

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![img133474293_0.jpg](img133474293_0.jpg) | Sheppard, Mullin, Richter & Hampton LLP<br>12275 El Camino Real, Suite 100<br>San Diego, CA 92130<br>www.sheppardmullin.com |

---

August 15, 2025

**<u>VIA E-MAIL</u>**

Lineage Cell Therapeutics, Inc.

Attn: Board of Directors

2173 Salk Avenue, Suite 200

Carlsbad, CA 92008

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the filing by Lineage Cell Therapeutics, Inc., a California corporation (the "Company"), of a Registration Statement on Form S-8 (the "Registration Statement") under the Securities Act of 1933, as amended (the "Securities Act"), with the Securities and Exchange Commission (the "SEC"), registering 19,500,000 common shares of the Company (the "Shares") that may be issued from time to time under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan (as amended to date, the "Plan").

This opinion is being furnished in accordance with the requirements of Item 8 of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.

In connection with this opinion, we have reviewed and relied upon the Registration Statement, the Company's restated articles of incorporation, as amended and in effect as of the date hereof (the "Articles of Incorporation"), the Company's amended and restated bylaws as in effect on the date hereof (the "Bylaws" and together with the Articles of Incorporation, the "Charter Documents"), the proceedings taken by the Company with respect to the authorization and adoption of the Plan, resolutions adopted by the board of directors of the Company, and such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion. With respect to the foregoing documents, we have assumed (a) the genuineness of all signatures, (b) the authenticity of all documents submitted to us as originals and (c) the conformity to originals of all documents submitted to us as certified or reproduced copies. We have further assumed that (i) the common shares currently reserved for issuance under the Plan will remain available for the issuance of the Shares, and (ii) neither the Charter Documents nor any of the proceedings relating to either the Plan or any of the award agreements relating to the Shares will be rescinded, amended or otherwise modified prior to the issuance of the Shares. We have also obtained from public officials and officers of the Company certificates or comparable documents as to certain factual matters and, insofar as this opinion is based on matters of fact, we have relied on such certificates and comparable documents without independent investigation.

On the basis of the foregoing examination and in reliance thereon, subject to the further provisions hereof, we are of the opinion that if, as and when the Shares are issued and sold by the Company in accordance with the terms of the award agreements provided for under the Plan, and payment in full of the consideration therefor is received by the Company, the Shares will be validly issued, fully paid and nonassessable.

We consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the SEC promulgated thereunder.

------

The foregoing opinion is limited to matters governed by the federal laws of the United States of America and the California General Corporation Law.

This opinion letter is rendered as of the date first written above solely for use in connection with the offer and sale of the Shares while the Registration Statement is in effect, and is not to be relied upon for any other purpose. We disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Shares, the Plan, the award agreements related to the Shares or the Registration Statement.

Respectfully,

<u>/s/ Sheppard, Mullin, Richter & Hampton LLP</u>

SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

------

## Exhibit 23.1

Exhibit 23.1

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Lineage Cell Therapeutics, Inc., of our report dated March 10, 2025, relating to the consolidated financial statements of Lineage Cell Therapeutics, Inc. (the "Company") as of and for the year ended December 31, 2024, (which report expresses an unqualified opinion), appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Baker Tilly US, LLP (formerly, Moss Adams LLP)

San Diego, California August 15, 2025

------

## Exhibit 23.2

Exhibit 23.2

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8, pertaining to the Lineage 2021 Equity Incentive Plan, constituting a part of this Registration Statement of our report dated March 7, 2024, except for Note 15, as to which the date is March 10, 2025, relating to the consolidated financial statements of Lineage Cell Therapeutics, Inc. ("the Company") as of and for the year then ended December 31, 2023, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

/s/ WithumSmith+Brown, PC

San Francisco, California

August 15, 2025

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107.1**

**Calculation of** Filing Fee **Table**

**Form** S-8

(Form Type)

Lineage Cell Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Security<br>type | **Security<br>class<br>title** | **Fee<br>calculation<br>rule** | &nbsp;&nbsp;&nbsp;&nbsp;**Amount<br>registered (1)** | **Proposed<br>maximum<br>offering<br>price per<br>unit (2)** | **Proposed<br>maximum<br>offering<br>price per<br>unit (2)** | **Maximum<br>aggregate<br>offering<br>price** | **Fee<br>rate** | **Amount of<br>registration<br>fee** |
| Equity | Common Shares | Other | 19500000 | $0.98 (3) | $19110000 | $19110000 | 0.0001531 | $2925.74 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | $19110000 |  | $2925.74 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  | $2925.74 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, this Registration Statement also covers such number of additional common shares that may become issuable under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan by reason of any stock split, stock dividend, recapitalization, or any other similar transaction effected that results in an increase to the number of outstanding common shares of the registrant.

(2) Estimated solely for the purpose of computing the registration fee in accordance with Rules 457(c) and 457(h) under the Securities Act of 1933.

(3) The proposed maximum offering price is based on the average of the high and the low prices per common share of the registrant as reported on the NYSE American as of a date (August 8, 2025) within five business days prior to the filing of this Registration Statement.

------